See why preliminary 2019 consensus-based forecasting has offered up a likely target of 28,000 on the Dow Jones industrial average in 2019.
Investors love their dividends. So 24/7 Wall St. has tracked the Dogs of the Dow strategy for years now.
The December 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
These six safer stocks all carry Merrill Lynch’s best volatility risk rating and pay dependable dividends. They offer reasonable entry points too.
GlaxoSmithKline shares bounced higher on Wednesday after the company announced a new joint venture with Pfizer. These two firms will create a premier global consumer health care company combining their robust iconic…
Elon Musk previews Los Angeles transportation tunnel, Pfizer and GlaxoSmithKline team up, stock buybacks hit a record this year, and other important business headlines today.
Douglas A. McIntyre These six Buy-rated stocks that have had a strong year and would be solid additions to portfolios for the end of 2018 and the beginning of 2019.
The November 30 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The included top analyst upgrades, downgrades and initiations seen on Tuesday Apptio, AT&T, Bain Capital, Comerica, First Solar, Palo Alto Networks, Pfizer, Travelers and Ulta Beauty.
The November 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Now that 2018 is nearing an end, it is a serious time for investors to start thinking about expectations in 2019 rather than looking back at how choppy 2018 has been.
24/7 Wall St. screened the Merrill Lynch research database for stocks rated Buy that pay a dividend and have the firm's best volatility risk rating. These five that look like solid picks…
The October 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased, with one major exception.
The demand for drugs to treat erectile dysfunction has risen to meet the needs of an aging population and to help combat disease-related causes.
Caterpillar, UnitedHealth, Microsoft, and Pfizer lifted the down to 500-point gain Wednesday.
